{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dogra S"],"funding":["ACADIA Pharmaceuticals","NIMH NIH HHS","Boehringer Ingelheim","NINDS NIH HHS","National Institutes of Health"],"pagination":["173493"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9729465"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["221"],"pubmed_abstract":["Glutamate is a major excitatory neurotransmitter in the central nervous system (CNS) and abnormalities in the glutamatergic system underlie various CNS disorders. As metabotropic glutamate receptor 3 (mGlu<sub>3</sub> receptor) regulates glutamatergic transmission in various brain areas, emerging literature suggests that targeting mGlu<sub>3</sub> receptors can be a novel approach to the treatment of psychiatric and neurological disorders. For example, mGlu<sub>3</sub> receptor negative allosteric modulators (NAMs) induce rapid antidepressant-like effects in both acute and chronic stress models. Activation of mGlu<sub>3</sub> receptors can enhance cognition in the rodents modeling schizophrenia-like pathophysiology. The mGlu<sub>3</sub> receptors expressed in the astrocytes induce neuroprotective effects. Although polymorphisms in GRM3 have been shown to be associated with addiction, there is not significant evidence about the efficacy of mGlu<sub>3</sub> receptor ligands in rodent models of addiction. Collectively, drugs targeting mGlu<sub>3</sub> receptors may provide an alternative approach to fill the unmet clinical need for safer and more efficacious therapeutics for CNS disorders."],"journal":["Pharmacology, biochemistry, and behavior"],"pubmed_title":["Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders."],"pmcid":["PMC9729465"],"funding_grant_id":["R01 NS031373","R01NS031373","R01MH062646","R01 MH074953","R01 MH119673","R01 MH062646"],"pubmed_authors":["Putnam J","Conn PJ","Dogra S"],"additional_accession":[]},"is_claimable":false,"name":"Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders.","description":"Glutamate is a major excitatory neurotransmitter in the central nervous system (CNS) and abnormalities in the glutamatergic system underlie various CNS disorders. As metabotropic glutamate receptor 3 (mGlu<sub>3</sub> receptor) regulates glutamatergic transmission in various brain areas, emerging literature suggests that targeting mGlu<sub>3</sub> receptors can be a novel approach to the treatment of psychiatric and neurological disorders. For example, mGlu<sub>3</sub> receptor negative allosteric modulators (NAMs) induce rapid antidepressant-like effects in both acute and chronic stress models. Activation of mGlu<sub>3</sub> receptors can enhance cognition in the rodents modeling schizophrenia-like pathophysiology. The mGlu<sub>3</sub> receptors expressed in the astrocytes induce neuroprotective effects. Although polymorphisms in GRM3 have been shown to be associated with addiction, there is not significant evidence about the efficacy of mGlu<sub>3</sub> receptor ligands in rodent models of addiction. Collectively, drugs targeting mGlu<sub>3</sub> receptors may provide an alternative approach to fill the unmet clinical need for safer and more efficacious therapeutics for CNS disorders.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T18:35:11.593Z","creation":"2025-04-19T18:35:11.593Z"},"accession":"S-EPMC9729465","cross_references":{"pubmed":["36402243"],"doi":["10.1016/j.pbb.2022.173493"]}}